A-PHP: Difference between revisions

Line 16:

==Pharmacology==

The mechanism of action ~~is unknown for~~ α-PHP. Aside from a substantially shorter duration, it is believed to act similarly to the [[designer drug]] [[pentedrone]] and [[α-PVP]], which both as a potent [[norepinephrine]]-[[dopamine]] [[reuptake inhibitor]]s (NDRI),<ref>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2602954</ref> although no substantial research on the pharmacology of this compound has yet been conducted.

The mechanism of action of α-PHP is unknown. Aside from a substantially shorter duration, it is believed to act similarly to the [[designer drug]] [[pentedrone]] and [[α-PVP]], which both as a potent [[norepinephrine]]-[[dopamine]] [[reuptake inhibitor]]s (NDRI),<ref>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2602954</ref> although no substantial research on the pharmacology of this compound has yet been conducted.

This means it may effectively boost the levels of the norepinephrine and dopamine neurotransmitters in the brain by binding to and partially blocking the transporter proteins that normally remove those monoamines from the synaptic cleft. This allows dopamine and norepinephrine to accumulate within the brain, resulting in [[stimulation|stimulating]] and [[physical euphoria|euphoric]] effects.

@@ Line 16: / Line 16: @@
 ==Pharmacology==
-The mechanism of action is unknown for α-PHP. Aside from a substantially shorter duration, it is believed to act similarly to the [[designer drug]] [[pentedrone]] and [[α-PVP]], which both as a potent [[norepinephrine]]-[[dopamine]] [[reuptake inhibitor]]s (NDRI),<ref>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2602954</ref> although no substantial research on the pharmacology of this compound has yet been conducted.
+The mechanism of action of α-PHP is unknown. Aside from a substantially shorter duration, it is believed to act similarly to the [[designer drug]] [[pentedrone]] and [[α-PVP]], which both as a potent [[norepinephrine]]-[[dopamine]] [[reuptake inhibitor]]s (NDRI),<ref>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2602954</ref> although no substantial research on the pharmacology of this compound has yet been conducted.
 This means it may effectively boost the levels of the norepinephrine and dopamine neurotransmitters in the brain by binding to and partially blocking the transporter proteins that normally remove those monoamines from the synaptic cleft. This allows dopamine and norepinephrine to accumulate within the brain, resulting in [[stimulation|stimulating]] and [[physical euphoria|euphoric]] effects.